

1 **Detection of Bourbon virus specific serum neutralizing antibodies in human serum**
2 **in Missouri, USA**

3
4 Gayan Bamunuarachchi^{1,#}, Houda Harastani^{1,#}, Paul W. Rothlauf^{3,6,#}, Ya-nan Dai⁴, Ali, Ellebedy⁴,
5 Daved Fremont^{4,5}, Sean P.J. Whelan³, David Wang^{3,4}, Adrianus C. M. Boon^{1,3,4}.

6
7 ¹ Department of Medicine, ³ Department of Molecular Microbiology, ⁴ Department of Pathology and
8 Immunology, and ⁵ Department of Biochemistry and Molecular Biophysics, at Washington
9 University School of Medicine in St. Louis.

10 ⁶Program in Virology, Harvard Medical School, Boston, MA, USA.

11 # Equal contribution

12
13 Lead Contact

14 Adrianus C. M. Boon
15 Department of Internal Medicine
16 Washington University in Saint Louis
17 School of Medicine
18 St. Louis, MO 63110

19 Email: jboon@wustl.edu

20 Running Title: Detection of Bourbon virus neutralizing antibody in human serum

21 Keywords: Bourbon virus, Seroprevalence, Human serum, Glycoprotein, monoclonal antibody,
22 Virus neutralization

23 **ABSTRACT**

24 Bourbon virus (BRBV) was first discovered in 2014 in a fatal human case. Since then
25 it has been detected in the *Amblyomma americanum* tick in the states of Missouri and
26 Kansas in the United States. Despite the high prevalence of BRBV in ticks in these states,
27 very few human cases have been reported, and the true infection burden of BRBV in the
28 community is unknown. Here, we developed two virus neutralization assays, a VSV-
29 BRBV pseudotyped rapid assay, and a BRBV focus reduction neutralization assay, to
30 assess the seroprevalence of BRBV neutralizing antibodies in human sera collected in
31 2020 in St. Louis, Missouri. Out of 440 human serum samples tested, three (0.7%) were
32 able to potently neutralize both VSV-BRBV and wild type BRBV. These findings suggest
33 that human infections with BRBV are more common than previously recognized.

34 **Importance**

35 Since the discovery of the Bourbon virus (BRBV) in 2014, a total of five human cases
36 have been identified, including two fatal cases. BRBV is thought to be transmitted by the
37 Lone Star tick, which is prevalent in the East, Southeast, and Midwest of the United States
38 (US). BRBV has been detected in ticks in Missouri and Kansas and serological evidence
39 suggests that it is also present in North Carolina. However, the true infection burden of
40 BRBV in humans is not known. In the present study, we developed two virus neutralization
41 assays to assess the seroprevalence of BRBV specific antibodies in human sera collected
42 in 2020 in St. Louis, Missouri. We found that a small subset of individuals is seropositive
43 for neutralizing antibodies against BRBV. Our data suggest that BRBV infection in
44 humans is more common than previously thought.

45

46 INTRODUCTION

47 Emerging and reemerging infectious diseases cause substantial global health and
48 socio-economic burden, and have a significant impact on human and animal life. Viral
49 pathogens, like Ebola virus, severe acute respiratory syndrome coronavirus-2 (SARS-
50 CoV-2), influenza virus, and Chikungunya virus, are among the most prominent emerging
51 zoonotic infections [1]. Many zoonotic diseases are transmitted by arthropod vectors such
52 as mosquitos and ticks and are an important cause of human morbidity and mortality in
53 the United States (US). Ticks are the main vector that transmit pathogens in the US
54 including four different viruses; Powassan virus, Colorado tick fever virus, Heartland virus
55 (HRTV), and Bourbon virus (BRBV).

56 BRBV belongs to the family *Orthomyxoviridae*, genus *Thogotovirus*. BRBV is a
57 negative-sense segmented RNA virus whose genome is composed of 6 gene segments
58 [2]. Segment 4 encodes the viral envelope glycoprotein (GP) that is necessary for virus
59 attachment and entry into cells [3], and it is the main target for virus neutralizing antibodies
60 [4]. A total of five human BRBV cases, including two fatal cases, have been reported since
61 the discovery of this virus in 2014. The first case of BRBV was an adult male patient from
62 Bourbon County, Kansas, USA. The patient was hospitalized with febrile illness and later
63 died from renal failure and acute respiratory distress syndrome. Subsequent culturing and
64 next-generation sequencing of the blood of this patient identified BRBV [5]. In 2017, a
65 state park official from Missouri was diagnosed positive for BRBV. This patient later died
66 of respiratory failure and cardiac complications [2, 6]. Both patients had reported tick
67 exposure and bites prior to becoming ill [2, 5].

68 BRBV is isolated from lone star ticks (*Amblyomma americanum*) [7-10]. These ticks
69 are abundant and aggressive human-biting ticks that are widely distributed across the
70 East, Southeast, and Midwest US [8, 11]. Rabbits fed on by BRBV-infected ticks
71 developed high antibody titers to the virus suggesting the lone star tick is a competent
72 vector of BRBV [10]. BRBV neutralizing antibodies have been identified in different wild
73 animal species. Using plaque-reduction neutralization test (PRNT), 50% and 86%
74 seroprevalence of BRBV neutralizing antibodies was found in sera from raccoons and
75 white-tailed deer in Missouri respectively [12]. Moreover, 56% seroprevalence was
76 observed in white-tailed deer sera from North Carolina [13]. These observations
77 demonstrate that the rate of infection of wild animals is significant, raising questions as to
78 the true infection rate and clinical burden of BRBV in humans.

79 Serology can provide an important benchmark on population immunity against
80 pathogens. However, to date there have been no serosurveillance studies assessing the
81 seroprevalence of BRBV specific neutralizing antibodies in humans in the US and world.
82 Thus the objectives of our study were to develop BRBV neutralization assays and
83 measure the human seroprevalence of BRBV infection. We found that nearly 1% of the
84 human sera, obtained in 2020, contained BRBV neutralizing antibodies. These data
85 suggest that BRBV infection in people is more common than previously thought.

86 MATERIALS AND METHODS

87 ***Virus and cell culture.*** Vero E6 and Vero-CCL81 cells were maintained in Dulbecco's
88 Modified Eagle Medium (DMEM) containing 4.5 g/L glucose, L-glutamine, and sodium
89 pyruvate (Corning) and supplemented with 10% Fetal Bovine Serum (FBS). Vero E6 cells
90 (ATCC) were grown in DMEM media (Corning Cellgro) supplemented with 5% FBS
91 (Biowest), 100 U/mL Penicillin (Life Technologies), 100 µg/mL streptomycin (Life
92 Technologies), and 2 mM L-Glutamine (Corning). Expi293F cells (Thermo Fisher
93 Scientific) used for transfection were maintained in Expi293 Expression Medium (Gibco).

94 VSV-eGFP-BRBV (herein VSV-BRBV) was generated by replacing the endogenous
95 G gene in a molecular cDNA of vesicular stomatitis virus (VSV), encoding eGFP, with a
96 codon-optimized version of the BRBV GP gene (Original strain, Kansas, Genbank
97 AMN92169.1). Virus rescue was performed as described [14]. Briefly, BSRT7/5 cells were
98 infected with vaccinia virus vTF7-3 and subsequently transfected with T7-driven helper
99 plasmids encoding VSV N, P, L, and G, and the VSV-BRBV cDNA. Cell supernatants
100 were harvested after 72 hours, centrifuged at 1,000 x g for 5 min, and passed through a
101 0.22 µm filter. Vero-CCL81 cells were then infected with rescue supernatants, and
102 plaques in agarose plugs were isolated and passed to Vero-CCL81 cells for p1 stock
103 generation. Working stocks were obtained by growing VSV-BRBV on Vero-CCL81 cells
104 at a multiplicity of infection of 0.01. RNA was extracted from virus stocks using the
105 QIAamp Viral RNA Mini Kit. RNA was reverse-transcribed using the QIAGEN OneStep
106 RT-PCR Kit with primers targeting VSV M-G (forward) and G-L (reverse) intergenic
107 regions. Stock sequences were confirmed by Sanger sequencing. BRBV (strain BRBV-

108 STL) [2] was grown on Vero E6 cells. Virus stocks were sequenced by next generation,
109 aliquoted, stored at -80°C, and used for all subsequent studies.

110 **VSV-BRBV characterization.** Vero-CCL81 cells were infected with eGFP-expressing
111 VSV (herein referred to as VSV) or VSV-BRBV at an MOI of 1. Cells were imaged 6 hours
112 post infection (hpi). Plaque assays were performed by infecting Vero-CCL81 cells with
113 the aforementioned viruses for 1 h at 37°C, after which the inoculum was removed, and
114 cells were overlaid with an agarose-containing overlay. Plates were imaged 24 hpi using
115 a biomolecular imager in the FITC channel.

116 **Recombinant proteins.** Recombinant BRBV GP (rGP, residues 20-485) was
117 expressed using the baculovirus expression system or transiently expression in
118 mammalian cell lines. For expressing with baculovirus expression system, the gene block
119 of BRBV GP ectodomain followed by a trimerization sequence
120 (GYIPEAPRDGQAYVRKDGWVLLSTFL) from the bacteriophage T4 fibrin and 6*His
121 tag at the extreme C-terminal was cloned into a modified pOET1 (Mirus Bio) baculovirus
122 transfer vector containing green fluorescent protein as an indicator [15]. Transfection and
123 amplification were carried out according to the *flashBAC* baculovirus expression system
124 manual (Mirus Bio). The High Five™ (Gibco) cell culture supernatant was harvested after
125 72 hpi, and concentrated before dialysis against buffer 20 mM NaHCO₃, 300 mM NaCl,
126 pH 8.0. BRBV GP ectodomain was captured by passaging the supernatant over Ni²⁺
127 affinity resin (GoldBio) and eluted with 500 mM imidazole (Sigma-Aldrich). The recovered
128 proteins were further applied to HiLoad 16/600 Superdex 200 column (GE healthcare) in
129 20 mM HEPES, 150 mM NaCl, and pH of 7.5. For expression in mammalian cells, the
130 gene fragment harboring the ectodomain, the trimerization domain as well as 6x-His tag

131 from the recombinant baculovirus vector was cloned into pFM1.2R vector [16] and
132 transiently expressed in Expi293F cells. The cell culture supernatant was harvested after
133 5 days post-transfection and concentrated before dialyzing against buffer 20 mM Tris-Cl
134 pH 8.5, 150 mM NaCl. Then the BRBV GP ectodomain protein was purified with the same
135 strategy as described above, with a combination of Ni affinity chromatography and size
136 exclusion chromatography.

137 ***Animal experiments.*** All animal experiments were performed according to the
138 Institutional Animal Care and Use Committee (IACUC) at Washington University in St.
139 Louis. Eleven-to-twelve weeks-old female C57BL/6 mice were obtained from Jackson
140 Laboratories. Mice (n = 3) were immunized intramuscularly with 500 ng of Beta-
141 propiolactone (BPL; Sigma-Aldrich) inactivated and purified BRBV complemented with
142 addavax (InvivoGen) (1:1, v:v) to generate BRBV GP specific monoclonal antibodies
143 (mAb). Four weeks later, the mice were immunized intramuscularly with 5 µg of
144 baculovirus-derived recombinant GP of BRBV complemented with addavax (1:1, v:v).
145 Sera was collected one day prior to each immunization and stored at -20°C. To generate
146 positive control sera, containing BRBV-specific neutralizing antibodies, we infected
147 C57BL/6 mice with 10⁴ infectious units of BRBV and collected sera at 22 days post
148 infection. Sera from five BRBV-infected mice were pooled together to use as the positive
149 control in the virus neutralization assays.

150 ***Flow cytometry.*** For B cell staining, spleen cells were collected five days post final
151 immunization and stained for 30 min on ice with CD16/CD32 (93; Biolegend® 1:100) and
152 biotinylated mammalian expressed rGP (1:100) diluted in PBS supplemented with 2%
153 FBS and 2 mM EDTA (P2). Next, the cells were washed twice with P2 and stained for 30

154 min on ice with anti-CD19-FITC (1D3; BioLegend® 1:100), anti-IgD-APC-Cy7-A (11-
155 26c.2a; BioLegend® 1:100), anti-Fas-PE-A (Jo2; BD Biosciences 1:200), anti-GL7-
156 PerCP-Cy5.5-A (GL7; BioLegend® 1:50), anti-CD71-PE-Cy7-A (RI7217; BioLegend®
157 1:100), anti-CD138-BV421 (281-2; BioLegend® 1:100), anti-CD4-AF700 (GK1.5;
158 BioLegend® 1:100) and Zombie Aqua (BioLegend® 1:200) diluted in Brilliant Stain buffer
159 (BD Horizon). After 30 min, the cells were washed twice with P2, after which they were
160 analyzed and single rGP-binding antibody-secreting B- cells (ASC; CD4⁻, CD19⁺, IgD^{lo},
161 CD95⁺, GL7⁻, CD138⁺, BRBV-GP⁺ live singlet lymphocytes) were sorted (n = 376) into
162 four 96-well plates containing 2 µL of Lysis Buffer (Clontech) supplemented with 1 U/µL
163 RNase inhibitor (New England BioLabs) with a FACSAria II and immediately frozen on
164 dry ice. Flow cytometry data were analyzed using FlowJo™ v.10.8.1.

165 ***Monoclonal antibody production.*** mAbs were generated as previously described
166 previously [17]. Briefly, variable heavy (VH) and variable light kappa and lambda (Vk and
167 Vλ, respectively) genes were amplified by RT-PCR and nested PCR from single-cell
168 sorted BRBV-GP specific ASCs using mixtures of primer sets specific for IgG, IgM/A, Igκ,
169 and Igλ using first-round and nested primer sets PCR products were then loaded on a 1%
170 agarose gel (Lonza), purified and then sequenced. Sequencing data was annotated using
171 IMGT/V-QUEST tool v3.5.28 on the ImMunoGenetTics database (available at
172 http://www.imgt.org/IMGT_vquest/) [18, 19]. Clonally related cells were identified by
173 similarity in variable heavy and light chain usage, CDR3 length, and amino-acid
174 composition. To generate recombinant mAbs, heavy chain V-D-J and light chain V-J
175 fragments were PCR amplified from first-round PCR products with mouse variable gene
176 forward primers and joining J gene reverse primers having 59 extensions for cloning by

177 Gibson assembly as previously described [20] and were cloned into pABVec6W Ab
178 expression vectors [21] in frame with either human IgG1, Igκ, or Igλ constant region.
179 Expression plasmids were sequence verified and transfected at a 1:2 ratio of heavy to
180 light chain ratio into Expi293F cells using the Expifectamine 293 Expression Kit (Thermo
181 Fisher Scientific). Culture supernatant was collected seven days post transfection and
182 mAbs, secreted into the supernatant, were purified with protein A agarose (Invitrogen),
183 and then stored at 4°C until further used.

184 ***Enzyme-linked immunosorbent assay (ELISA).*** Ninety-six well microtiter plates
185 (Thermo Fisher Scientific) were coated overnight at 4°C with 1 µg/mL of baculovirus
186 expressed rGP in PBS. After washing the wells 3x with 280 µL PBS-T (PBS supplemented
187 with 0.05% Tween-20), wells were blocked with 280 µL of PBS supplemented with 10%
188 FBS and 0.05% Tween-20 (blocking buffer) for 1.5 h at room temperature (RT). Blocking
189 buffer was removed, and 3-fold serial dilutions starting from 1:30 for mouse polyclonal
190 sera or 30 µg/mL for mAbs were added and incubated for 1 h at RT. An influenza A virus
191 specific mAb (1C11) specific for the hemagglutinin of A/Puerto Rico/8/1934 was used as
192 a negative control. Plates were washed 3x with PBS-T. mAbs were detected using goat-
193 anti-human IgG-HRP (Jackson ImmunoResearch, Cat no. 109-035-088) while mouse
194 sera were detected using goat-anti-mouse IgG1-HRP (Southern Biotech, Cat no. 1070-
195 05) diluted 1:1000 in blocking buffer for 1 h at RT. After washing 3x with PBS-T followed
196 by 3x with PBS, the assay was developed with 100 µL of substrate solution (phosphate-
197 citrate buffer with 0.1% H₂O₂ and 0.4 mg/mL o-Phenylenediamine dihydrochloride (OPD,
198 Sigma-Aldrich)) was added to all wells and incubated for 5 min before the reaction was

199 stopped with 1M HCl (100 μ L). Optical density measurements were taken at 490 nm using
200 a microtiter plate reader (BioTek).

201 **Focus forming assay (FFA).** Monolayers of Vero E6 cells, seeded in 96 well tissue
202 culture treated plates, were washed once with PBS and incubated with VSV-BRBV or
203 BRBV diluted in serum free DMEM (Corning). After 1 h at 37°C, the inoculum was
204 aspirated, the cells were washed with PBS, and 100 μ L of 1% methylcellulose (Sigma) in
205 1x minimum essential media (MEM, Corning) supplemented with 2% FBS (Biowest) was
206 added to each well. The cells were incubated for 24 h at 37°C/5% CO₂ before the
207 monolayer was fixed with 100 μ L of 5% Formalin (Fisher Chemicals) for 1 h at RT. Cells
208 were washed with PBS and subsequently incubated with the BRBV-GP specific mAb E02
209 in PBS-T plus 1% bovine serum albumin (BSA, Sigma) . After 1 h incubation at RT, the
210 cells were washed three times with PBS-T and incubated with HRP-conjugated goat anti-
211 human IgG (Sigma) diluted in PBS-T + 1% BSA for 1 h at RT. Finally, cells were washed
212 three times with PBS-T, and VSV-BRBV or BRBV infected cells were visualized using
213 TMB substrate (Vector laboratories) and quantitated on an ImmunoSpot[®] Analyzer
214 (Cellular Technologies).

215 **Human serum cohort.** We screened 440 adult serum samples that were part of a set
216 of residual samples sent to Barnes-Jewish Hospital, Missouri for physician-ordered
217 vitamin D testing between 27 April 2020 and 12 May 2020 [22]. This study was approved
218 by the Human Research Protection Office at Washington University in St. Louis (approval
219 no. 202004199).

220 **Rapid eGFP-based VSV-BRBV-GP virus neutralization assay.** Vero E6 cells were
221 cultured overnight in tissue culture treated black 96-well plates (Corning). Human sera

222 were heat-inactivated at 56°C for 30 min and serially diluted 1:10 and 1:30 in serum free
223 DMEM (DMEM-SF). The next day 200 focus forming units (FFU) of VSV-BRBV virus
224 diluted in an equal volume of DMEM-SF were added to the diluted human serum samples
225 (final serum dilution is 1:20 and 1:60) and incubated for 1 h at RT. Next, the antibody
226 virus complexes were added to the Vero E6 cells that were washed once with PBS and
227 incubated for 8 h at 37°C. Each serum sample and dilution was tested in duplicate and
228 each assay included a positive control mouse serum sample, and no serum controls
229 (DMEM media only). After 8 h the cells were fixed with an equal volume of 10% formalin
230 containing 10 µg/mL Hoechst (Sigma) was added to each well for 1 h at RT.
231 Subsequently, cells were washed once with PBS, and images were acquired with the
232 InCell 2000 Analyzer (GE Healthcare). This automated microscope contains both FITC
233 and DAPI channels to visualize infected cells (i.e. eGFP-positive cells) and nuclei
234 respectively. Each well is divided into 4 fields that are imaged with a 4x objective lens.
235 Subsequently, cumulative eGFP-positive cells and nuclei of the 4 fields were counted.
236 Images were analyzed using the Multi-Target Analysis Module of the InCell Analyzer 1000
237 Workstation Software (GE Healthcare). eGFP-reduction neutralization activity of the
238 serum samples was calculated by dividing the number of eGFP positive cells for each
239 serum sample by the average number of eGFP positive cells in the no serum control
240 wells.

241 ***BRBV neutralization assay.*** A focus reduction neutralization assay (FRNT) was
242 developed for BRBV. Vero E6 cells were seeded overnight in tissue-cultured treated 96-
243 well plates (Corning). Heat-inactivated human or mouse sera were diluted 1:20 in DMEM-
244 SF media and subsequently serially diluted 3-fold to a final dilution of 1:14580. Next, an

245 equal volume of DMEM-SF containing 200 FFU of BRBV was added to each serum
246 dilution and incubated for 1 h at RT. The addition of the virus resulted in a final serum
247 dilution of 1:40 to 1: 29160. Next, the Vero E6 cells were washed once with PBS and the
248 antibody-virus complexes were transferred to cells and incubated for 1 h at 37°C. Each
249 serum sample and dilution was tested in duplicate and each assay included positive
250 (pooled convalescent sera from BRBV infected mice), negative serum, and no serum
251 controls. After 1 h at 37°C, the cells were washed once with PBS and 100 µL of MEM
252 containing 2% FBS and 1% methylcellulose was added to each well. After 24 h at 37°C,
253 the cells were fixed by adding 100 µL of 10% Formalin on top of the overlay (final
254 concentration 5% Formalin) for 1 h at RT. Subsequently, cells were washed with PBS
255 and the assay was developed as described above for the focus forming assay. The
256 percent inhibition of BRBV infection was calculated by dividing the number of foci in the
257 test sample by the average number of foci in the no serum control wells.

258 **Statistical analysis.** Data were analyzed by using GraphPad Prism version 9.3.1
259 software. EC₅₀ and IC₅₀ values were calculated by using log (inhibitor) vs response in
260 variable slope (four parameters) fixing both bottom and top constrain at 0 and 100
261 respectively.

262 RESULTS

263 **Construction of a replication-competent VSV expressing BRBV GP.** Since
264 authentic BRBV is a biosafety level 3 (BSL3) pathogen, we sought to develop a tool to
265 study aspects of the BRBV lifecycle at reduced biocontainment. To do this, we replaced
266 the glycoprotein gene in a molecular clone of eGFP-expressing VSV with the GP gene of
267 BRBV (VSV-BRBV) (**Fig 1A**). VSV-BRBV was capable of robust eGFP expression in
268 Vero-CCL81 and grew to high titers ($>10^8$ FFU/mL) with similar plaque size to VSV
269 containing its native glycoprotein (**Fig 1B, C**).

270 **Development of humanized monoclonal antibodies against GP of BRBV.** Eleven-
271 to-twelve weeks-old C57BL/6 mice were immunized intramuscularly with inactivated
272 BRBV followed by a single intramuscular boost with rGP of BRBV 33 days later. Sera
273 were collected 21 and 5 days after the first and second immunization respectively (**Fig**
274 **2A**) and used to measure GP specific antibody responses by ELISA. Compared to the
275 primary immunization, mice boosted with rGP of BRBV showed ~6-fold increase in serum
276 antibody titer for binding to BRBV rGP (**Fig 2B**). Five days after the boost, the spleens
277 from one immunized and a control animal were isolated and processed for detection and
278 isolation of BRBV GP-specific B cells. Nearly 2% of the ASC B-cells ($CD4^-$, $CD19^+$, IgD^{lo} ,
279 $CD95^+$, $GL7^-$, $CD138^+$) were specific for BRBV-GP (**Fig 2C**). No BRBV-GP specific ASC
280 B-cells were detected in the naïve control animal. The BRBV-GP labelled B cells were
281 then single cell sorted by FACS into 96-well plates containing lysis buffer. Amplification
282 of VH , $V\kappa$, and $V\lambda$ genes from a single B-cell sorted 96-well plate showed ~70%
283 productive V-domains ($n= 66/94$) which were later grouped into nine different clonal
284 groups based the identity of their V and J alleles and the CDR3 region. One representative

285 VH and VL gene from each clonal group were cloned into human IgG1 expression
286 vectors, transfected in HEK293 cells, and purified. These mAbs are further referred to as
287 BRBV-GP-A05, -A08, -A10, -B02, -B03, -B04, -E02, -E04, and -F07. Purified mAbs were
288 tested for specificity and affinity to rGP by ELISA (**Fig 2D**). All nine antibodies were
289 specific for BRBV-GP, three (BRBV-GP-A05, -A08, and -B02) of which demonstrated
290 binding affinity to BRBV rGP with an $EC_{50} < 500$ ng/mL.

291 The mAbs were further evaluated in a FFA with BRBV for their ability to detect surface
292 expressed GP on infected cells. In cells infected with BRBV, only two of the nine tested
293 mAbs (B02, and E02) were able to detect the GP protein on the surface of infected cells
294 and produce distinct foci in this assay (**Fig 2E**). The remaining seven mAbs were unable
295 to detect GP expression in BRBV-infected Vero E6 cells. Of the two mAbs, E02 produced
296 the most distinct and intense foci in the BRBV FFA (**Fig 2E**). This data combined with the
297 ELISA data (**Fig 2D**), demonstrate that we produced the first BRBV specific monoclonal
298 antibodies that can be used for diagnostic assays.

299 ***A rapid, eGFP-based neutralization assay for BRBV.*** To facilitate throughput and
300 reduce the costs associated with BSL3 work, we developed a rapid and high-throughput
301 eGFP-based neutralization assay using a replication competent BRBV-GP pseudotyped
302 VSV that also expressed eGFP (VSV-BRBV). To demonstrate the utility of this virus, cells
303 were inoculated with 200 FFU of VSV-BRBV with or without sera containing neutralizing
304 antibodies against BRBV. After 8 h without serum, eGFP expression is clearly visible in
305 a subset of the cells (**Fig 3A, left panel**). The addition of mouse sera obtained from naïve
306 C57BL/6 animals did not inhibit the infection and replication of VSV-BRBV and similar
307 number of eGFP positive cells were visible (**Fig 3A, middle panel**). In contrast, the

308 addition of serum collected 22 days after inoculation of C57BL/6 mice with 10^4 infectious
309 units of BRBV, completely neutralized VSV-BRBV and no eGFP-positive cells were
310 detected (**Fig 3A, right panel**). Analysis of the positive and negative control sera show a
311 significant difference ($P < 0.0001$) in neutralization of VSV-BRBV (**Fig 3B**). Combined,
312 these data show that VSV-BRBV can be used as a high-throughput alternative for live
313 BRBV to detect BRBV neutralizing antibodies.

314 A total of 440 human serum samples were tested in the rapid VSV-BRBV based
315 neutralization assay at two different dilutions of the sera (1:20 and 1:60). The inhibition of
316 VSV-BRBV infection was normalized to the no serum control wells included in each
317 assay. The vast majority of the sera did not neutralize VSV-BRBV at either the 1:20 or
318 1:60 dilution of the sera (**Fig 3C**). Interestingly, three human serum samples
319 demonstrated $> 80\%$ reduction in VSV-BRBV infection at both serum dilutions (**Fig 3C**).
320 In addition, 54 and 14 sera were identified as potentially positive ($> 60\%$, but $< 80\%$
321 inhibition) at the 1:20 and 1:60 dilution of the sera respectively (**Fig 3C**). The 14 samples,
322 identified as potentially positive in 1:60 dilution, were also potentially positive in 1:20
323 dilution and selected for further testing in the BRBV FRNT assay together with 3 positive
324 samples.

325 ***Neutralization of BRBV by human serum samples.*** To confirm our findings and
326 demonstrate neutralizing of live BRBV by antibodies in human sera, we developed a
327 FRNT for BRBV using the BRBV-GP specific mAb (E02) described above. Sera collected
328 from naïve mice was unable to neutralize BRBV and the number of foci was comparable
329 to the no serum controls (**Fig 4A, left panel**). In contrast, convalescent sera from mice

330 infected with BRBV was able to potently neutralize live BRBV (**Fig 4A, right panel**). The
331 IC_{50} for these sera ranged between 1:500 and 1:1350.

332 Next, the BRBV FRNT assay was used to test the 17 human serum samples that
333 previously demonstrated complete or partial neutralization of VSV-BRBV (**Fig 3C**). The
334 three serum samples that strongly inhibited (> 80% inhibition) VSV-BRBV also inhibited
335 BRBV in the FRNT assay (**Fig 4B, left panel**). The IC_{50} values for these three serum
336 samples were 1:2631, 1:1259 and 1:938. The remaining 14 human serum samples that
337 partially inhibited VSV-BRBV infection (> 60%, but <80% inhibition) did not neutralize
338 BRBV in the FRNT assay (**Fig 4B, middle panel**). As a control we tested 19 human
339 serum samples that did not neutralize VSV-BRBV. None of the 19 control sera were able
340 to inhibit BRBV infection and their IC_{50} values were at the limit of detection (1:40) (**Fig**
341 **4B, right panel**). Collectively, these data demonstrate that BRBV infections occur in the
342 St Louis community and that the seroprevalence of BRBV neutralizing antibodies is
343 ~0.7%.

344 **DISCUSSION**

345 Here we defined the first seroprevalence of BRBV serum neutralizing antibodies in
346 human sera collected from the greater St. Louis Metropolitan area. We developed two
347 virus neutralization assays, a rapid VSV-BRBV eGFP based neutralization assay, and a
348 BRBV focus reduction neutralization assay, to systematically evaluate the presence of
349 BRBV neutralizing antibodies in human serum. These assays identified 3 (0.7%) human
350 sera that contained BRBV specific neutralizing antibodies. These finding indicate that the
351 incidence of BRBV infection in the St. Louis region in Missouri, US is higher than
352 previously expected based simply on confirmed cases that have been reported.

353 BRBV is classified as a BSL3 pathogen and needs specialized laboratories, training,
354 and equipment to work with. As such, limited labs in the US and around the world have
355 the capacity to work with live BRBV. To facilitate the testing of BRBV-GP specific
356 countermeasures and determine the seroprevalence of neutralizing antibodies in humans
357 and wildlife, we developed a rapid eGFP-based neutralization assay using replication-
358 competent VSV expressing both eGFP and BRBV GP. This virus can be used at lower
359 biosafety containment levels (BSL2). Importantly, compared to previously described
360 methods such as PRNT, both the eGFP-based rapid assay and the BRBV FRNT can be
361 used to evaluate BRBV neutralizing antibodies within three days. Thus the turnaround
362 time is greatly improved.

363 One of the major limitation of studying emerging pathogens is the lack of reagents
364 such as mAbs, recombinant proteins, reporter viruses etc. This is the first report
365 describing mAbs specific for GP of BRBV. Two of these mAbs were able to detect GP

366 expression on cells infected with BRBV. Unfortunately, these antibodies did not neutralize
367 BRBV, suggesting they do not bind the receptor binding site of the virus [3].

368 BRBV and HRTV are classified as emerging infectious diseases that are transmitted
369 via ticks in the US. A previous study demonstrated a 0.9% seroprevalence of HRTV
370 specific neutralizing antibodies in northwestern Missouri, US, where human cases and
371 infected ticks have been identified [23]. Our study demonstrates a 0.7% seroprevalence
372 of BRBV specific neutralizing antibodies in individuals in the St. Louis area. This is the
373 first time that BRBV neutralizing antibodies have been reported in individuals without a
374 prior history of BRBV infection. These data also suggest that the true infection burden of
375 BRBV in humans is much higher than previously expected. The seroprevalence in this
376 cohort may underestimate the true infection rate and burden. First, our human serum
377 cohort is from the greater St. Louis area and is likely composed primarily of urban
378 populations that are less likely to be exposed to BRBV infected ticks. Future
379 seroprevalence studies with sera from individuals living in rural areas where BRBV
380 infection in ticks have been reported are needed. Second, the presence of detectable
381 levels of neutralizing antibodies is a relatively high threshold for determining prior infection
382 with any virus including BRBV. For example, there are many individuals previously
383 infected with the influenza virus or severe acute respiratory syndrome coronavirus 2
384 (SARS-CoV-2) who have no detectable serum neutralizing antibodies. Moreover, the true
385 infection burden of BRBV in US could be underestimated due to lack of diagnostic testing,
386 unknown virus geographical distribution, and unknown rate of asymptomatic infections.
387 Combined with the widespread distribution of the lone star tick and the reported presence
388 of BRBV-specific antibodies in North Carolina, we expect the true infection burden of

389 BRBV to be much higher than what was previously expected based on the number of
390 confirmed BRBV infections per year.

391 Three human sera showed the highest neutralization activity (> 80% inhibition) in the
392 VSV-BRBV eGFP-based assay. These same samples were confirmed positive for BRBV-
393 specific neutralizing antibody by FRNT. These findings suggest that the rapid assay and
394 the BRBV FRNT are consistent in detecting the true seropositive samples and that our
395 cut-off of 80% is rigorous. These two BRBV neutralization assays will expand our
396 knowledge of BRBV seroprevalence in humans and in wild animals. Previous studies
397 have shown that serum from white-tailed deer, raccoons, domestic dogs, horses, and
398 eastern cottontails also contains BRBV neutralizing antibodies [12, 13]. The assays
399 developed in this study will facilitate additional testing of animal species in BRBV endemic
400 and non-endemic areas and help identify the breadth of host species affected by this
401 virus.

402 In conclusion, our study established two neutralization assays for BRBV and for the
403 first time evaluated BRBV seroprevalence in a cohort of human sera. We found 3 people
404 that were positive for BRBV neutralizing antibodies.

405

406 **ACKNOWLEDGEMENTS**

407 We thank Maxene Ilagan at Washington University School of Medicine High
408 Throughput Center for supporting with imaging. This study was supported by NIH/NIAID
409 grants R21 AI151170 and U01 AI151810. P.W.R. is supported by 1F31AI154710-01A1.

410

411

412 **AUTHOR CONTRIBUTIONS**

413 G.B. and P.W.R. designed experiments. G.B. performed the neutralization assays.
414 H.H. and A.E. generated and tested the monoclonal antibodies. P.W.R. and S.P.J.W.
415 generated and characterized the VSV-BRBV virus. Y.D. and D.F. generated the
416 recombinant glycoproteins. D.W. collected human serum samples. A.C.M.B. obtained the
417 funding. G.B., H.H., P.W.R., and A.C.M.B. wrote the manuscript, and all authors edited
418 the final version.

419 REFERENCES


- 420 1. Morens, D.M. and A.S. Fauci, *Emerging Pandemic Diseases: How We Got to COVID-19*. Cell,
421 2020. **182**(5): p. 1077-1092.
- 422 2. Bricker, T.L., et al., *Therapeutic efficacy of favipiravir against Bourbon virus in mice*. PLoS Pathog,
423 2019. **15**(6): p. e1007790.
- 424 3. Bai, C., et al., *Postfusion structure of human-infecting Bourbon virus envelope glycoprotein*. J
425 Struct Biol, 2019. **208**(2): p. 99-106.
- 426 4. Jones, L.D., et al., *Immune protection conferred by the baculovirus-related glycoprotein of*
427 *Thogoto virus (Orthomyxoviridae)*. Virology, 1995. **213**(1): p. 249-53.
- 428 5. Kosoy, O.I., et al., *Novel thogotovirus associated with febrile illness and death, United States,*
429 *2014*. Emerg Infect Dis, 2015. **21**(5): p. 760-4.
- 430 6. Miller, M. *Bourbon Virus Now Listed as Emerging Illness — New Case in St. Louis County*. 2018
431 [cited 2021 11/10/21]; Available from:
432 [https://www.emissourian.com/local_news/county/bourbon-virus-now-listed-as-emerging-](https://www.emissourian.com/local_news/county/bourbon-virus-now-listed-as-emerging-illness-new-case-in-st-louis-county/article_5d67a0e6-bf55-5cfb-9e6c-9b73896fafad.html)
433 [illness-new-case-in-st-louis-county/article_5d67a0e6-bf55-5cfb-9e6c-9b73896fafad.html](https://www.emissourian.com/local_news/county/bourbon-virus-now-listed-as-emerging-illness-new-case-in-st-louis-county/article_5d67a0e6-bf55-5cfb-9e6c-9b73896fafad.html).
- 434 7. Lambert, A.J., et al., *Molecular, serological and in vitro culture-based characterization of*
435 *Bourbon virus, a newly described human pathogen of the genus Thogotovirus*. J Clin Virol, 2015.
436 **73**: p. 127-132.
- 437 8. Savage, H.M., et al., *Bourbon Virus in Field-Collected Ticks, Missouri, USA*. Emerg Infect Dis, 2017.
438 **23**(12): p. 2017-2022.
- 439 9. Savage, H.M., et al., *Surveillance for Tick-Borne Viruses Near the Location of a Fatal Human Case*
440 *of Bourbon Virus (Family Orthomyxoviridae: Genus Thogotovirus) in Eastern Kansas, 2015*. J Med
441 Entomol, 2018. **55**(3): p. 701-705.
- 442 10. Godsey, M.S., et al., *Experimental Infection of Amblyomma americanum (Acari: Ixodidae) With*
443 *Bourbon Virus (Orthomyxoviridae: Thogotovirus)*. J Med Entomol, 2021. **58**(2): p. 873-879.
- 444 11. Savage, H.M., et al., *Surveillance for Heartland and Bourbon Viruses in Eastern Kansas, June*
445 *2016*. J Med Entomol, 2018. **55**(6): p. 1613-1616.
- 446 12. Jackson, K.C., et al., *Bourbon Virus in Wild and Domestic Animals, Missouri, USA, 2012-2013*.
447 Emerg Infect Dis, 2019. **25**(9): p. 1752-1753.
- 448 13. Komar, N., et al., *Indirect Evidence of Bourbon Virus (Thogotovirus, Orthomyxoviridae) Infection*
449 *in North Carolina*. N C Med J, 2020. **81**(3): p. 214-215.
- 450 14. Case, J.B., et al., *Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent*
451 *VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2*. Cell host & microbe, 2020. **28**(3): p. 475-
452 485.e5.
- 453 15. Stevens, J., et al., *Structure and receptor specificity of the hemagglutinin from an H5N1 influenza*
454 *virus*. Science, 2006. **312**(5772): p. 404-10.
- 455 16. Wang, X., et al., *A herpesvirus encoded Qa-1 mimic inhibits natural killer cell cytotoxicity through*
456 *CD94/NKG2A receptor engagement*. Elife, 2018. **7**.
- 457 17. von Boehmer, L., et al., *Sequencing and cloning of antigen-specific antibodies from mouse*
458 *memory B cells*. Nature Protocols, 2016. **11**(10): p. 1908-1923.
- 459 18. Brochet, X., M.P. Lefranc, and V. Giudicelli, *IMGT/V-QUEST: the highly customized and*
460 *integrated system for IG and TR standardized V-J and V-D-J sequence analysis*. Nucleic Acids Res,
461 2008. **36**(Web Server issue): p. W503-8.
- 462 19. Giudicelli, V., X. Brochet, and M.P. Lefranc, *IMGT/V-QUEST: IMGT standardized analysis of the*
463 *immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences*. Cold Spring Harb Protoc,
464 2011. **2011**(6): p. 695-715.

- 465 20. Ho, I.Y., et al., *Refined protocol for generating monoclonal antibodies from single human and*
466 *murine B cells*. J Immunol Methods, 2016. **438**: p. 67-70.
- 467 21. Davis, C.W., et al., *Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection*.
468 Cell, 2019. **177**(6): p. 1566-1582.e17.
- 469 22. Smith, B.K., et al., *Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis,*
470 *Missouri, USA*. mSphere, 2021. **6**(1).
- 471 23. Lindsey, N.P., et al., *Seroprevalence of Heartland Virus Antibodies in Blood Donors, Northwestern*
472 *Missouri, USA*. Emerg Infect Dis, 2019. **25**(2): p. 358-360.


473

474 **FIGURE LEGENDS**


A



B



C



475

Figure 1


476 **Figure 1: Generation of a replication-competent VSV expressing eGFP and BRBV GP. (A)**

477 Genome schematic. Genes encoded by each virus are to scale (except Le – Leader and Tr –
478 Trailer) and are indicated by eGFP (enhanced green fluorescent protein), N (nucleoprotein), P
479 (phosphoprotein), M (matrix protein), G or GP (glycoprotein), and L (large protein or polymerase).

480 Glycoprotein gene length excludes the stop codon. (B) Vero-CCL81 were infected with VSV or

481 VSV-BRBV at an MOI of 1 images were acquired 6 hours post infection (hpi). (C) Representative

482 plaque assay of VSV or VSV-BRBV on Vero-CCL81 cells. Images were acquired 24 hpi.




483
484 **Figure 2: Generation and characterization of humanized monoclonal antibodies against**
485 **BRBV GP.** (A) Immunization regimen. 11-12 weeks old C57BL/6 mice were immunized
486 intramuscularly with 500 ng BPL-inactivated BRBV, followed by boosting with 5 µg of rGP of
487 BRBV 33 day later. Sera was collected at days 21 and 38. Spleens were harvested five days post
488 boost (day 38) (B) IgG serum Ab ELISA for rGP of BRBV for naïve and immunized mice at days
489 21 and 38. Results are average of two independent experiments. (C) Representative plots of
490 BRBV-GP specific ASC B-cells (CD4⁺, CD19⁺, IgD^{lo}, CD95⁺, GL7⁻, CD138⁺, BRBV-GP⁺ live singlet
491 lymphocytes) in naïve mice (top) and BRBV-immunized mice (bottom) (D) ELISA measuring
492 binding of nine mAbs to rGP of BRBV. Each line is a different antibody and the results are the
493 average of two independent experiments. (E) Binding of mAb B02 and E02 to BRBV-infected
494 cells. Vero cells were infected with ~100 infectious units of BRBV for 24 h, fixed with 5% formalin,

Figure 2

495 and virus-infected cells were visualized by incubating the cells with 2-3 $\mu\text{g}/\text{mL}$ of mAbs B02 and
496 E02, or a control. Images are representative of 2 experiments.

497

498



499

Figure 3

500

501 **Figure 3: Development of a rapid eGFP-based BRBV neutralizing assay.** (A) Effective
502 neutralization of VSV-BRBV by BRBV-neutralizing antibodies. Monolayers of Vero cells incubated
503 for 8 h with VSV-BRBV, expressing eGFP, in the presence of mouse serum-containing BRBV
504 neutralizing antibodies (positive control), control mouse serum, or no serum were visualized with
505 DAPI (blue color). VSV-BRBV infected cells were visualized by the expression of GFP from the
506 VSV genome. Representative images of the no serum (left), negative serum (middle), and positive
507 serum (right) controls are shown at 4x magnification. (B) Normalized VSV-BRBV neutralization
508 (% inhibition compared to no serum control) of the positive and negative control sera. Each symbol
509 is an individual mouse serum sample (n = 15 negative control, n = 5 positive control) (C)
510 Normalized VSV-BRBV infection (% inhibition compared to no serum control) of 440 human
511 serum samples at a 1:20 (left panel) and 1:60 (right panel) dilution of the sera. Each symbol is a
512 serum sample. The dotted lines represent the cut-offs for 60% and 80% inhibition.




Figure 4

513
514
515 **Figure 4: Detection of serum neutralizing antibodies against BRBV in human serum**
516 **samples.** A focus reduction neutralization test (FRNT) was developed for BRBV. Serially diluted
517 heat-inactivated human or mouse sera (starting at 1:40 dilution) was incubated for 1 h with 100
518 focus forming units of BRBV prior to adding it to Vero cells. One h later, the inoculum was
519 removed, the cells were overlaid with 1% methylcellulose, and incubated for 24 h. Clusters of
520 infected cells (foci) were visualized using the E02 mAb as described in the Materials and Methods
521 section. The number of foci are normalized to no serum controls. (A) *Left.* FRNT with serum from
522 mock-infected control animals. No BRBV neutralizing activity was detected in the negative control
523 sera. *Right.* FRNT demonstrating virus-neutralizing activity in convalescent serum collected from
524 C57BL/6 mice 22 days after inoculation with 10⁴ PFU of BRBV. Neutralization of BRBV was
525 detected in all five mouse serum samples. (B) FRNT on human serum samples with distinct

526 neutralizing activities in the rapid assay. Human serum samples showing complete neutralization
527 (0-20%, *left*), partial neutralization (20-40%, middle), or no neutralization (100%, right) in the VSV-
528 BRBV rapid assay were tested by FRNT. Three human sera were able to neutralized BRBV by
529 FRNT.